MRFR asserts that the global Intravenous Immunoglobulin market growing further will reach USD 8337.2 Million by 2023, registering ~5.9% CAGR during 2017 to 2023.
Intravenous Immunoglobulin Market – Synopsis
Acknowledging the kind of the growth the market perceives currently; Market Research Future (MRFR) has recently published a study report giving out the complete market forecast up to 2023. In its analysis,
Immunodeficiency disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factors too that could put someone at higher risk of a damaged immune system.
Get free Sample Copy of this report at : https://www.marketresearchfuture.com/sample_request/3137
Some of the fervent key players, including Baxter (US), Abeona Therapeutics (US), BDI Pharma (US), China Biologic Products, Inc. (China), Biotest AG. (Germany), Grifols Inc. (Spain), CSL Behring (US), Kedrion S.p.A (US), Octapharma (Switzerland), and Shire (Republic of Ireland) lead the global Intravenous Immunoglobulin market. Profiling them in its analysis MRFR finds out their strategies keeping them at the forefront of the market competition.
Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with the inefficient or damaged immune systems. IVIg suffices the required antibodies by the human body to fight out the immune deficiency, and the consequent infectious attacks. Immunodeficiency Disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factor too that could put someone at greater risk of a damaged immune system.
Leveraging to the modern age, people have adopted the heady & unhealthy lifestyles which mirror the prevalence of damaged immune system. Factors such as immense of stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the prevalence of Immunodeficiency Disorder. And, the augmented prevalence is predominantly driving the market growth.
The augmenting demand for alternate immunoglobulin replacement therapies, increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are major driving forces for the market growth. Technological advancements transpired in the medical science, are fostering the market growth exponentially, bringing up novel treatment procedures, & medications in the field of IVIg.
Additionally, factors such as growing population and geriatric populace worldwide are fostering the market growth. Improving economic conditions are providing impetus to the market growth, enabling access to the quality life & to the improved healthcare. Seminal efforts &investments put in the development of IVIg, by the key market players are paying off well, driving the market growth.
On the other hand, factors such as low awareness among people about the availability of treatment, the high cost of IVIg management along with the skepticism towards the advancement & efficacies of these treatments among the patients are likely to impede the growth of the Intravenous Immunoglobulin market.
Global Intravenous Immunoglobulin Market – Competitive Analysis
The global IVIg market is fiercely competitive with the presence of several large and small players operating in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The market structure is dynamic due to the acquisition of local manufactures by the multinational companies. Strategies like product innovations and technologies are creating strong investment opportunities for the market players.
Industry, Innovation & Related News
May 04, 2018 – Evolve Biologics, (a division of Therapure Biopharma Inc. – US), a leading global player involved in development and commercialization of plasma-derived therapeutics announced that the clinical trial of its PlasmaCap™ IG (Intravenous Immunoglobulin) had exhibited favorable results when administered on the first pediatric patient. The adult portion of PlasmaCap™ IG has already received the approval from FDA in Fab.2018.
Intravenous Immunoglobulin Market – Segments
For the convenience of the report and enhanced understanding; MRFR has segmented the market into three key dynamics
By Types : Comprises IgA, (IgA1 & A2), IgD, IgE, IgG, IgM).
By Applications : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP – progressive, recurrent, monophasic), Hypogammaglobulinemia Multifocal Motor Neuropathy (AGM1, AGM2, AGM3, AGM4, AGM5, AGM6),
Immunodeficiency Diseases (XLA (X-linked agammaglobulinemia), CVID (common variable immunodeficiency), SCI (severe combined immunodeficiency), Primary
Humoral Immunodeficiency {B cell (antibody) & T cell deficiencies, Combination B and T cell deficiencies, DPCD (defective phagocytes, complement deficiencies)},
Unknown (idiopathic) Immunodeficiency diseases, Myasthenia Gravis (Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Transient Neonatal Myasthenia Gravis), Guillain-Barre syndrome{AIDP (acute inflammatory demyelinating polyradiculoneuropathy), MFS (miller fisher syndrome), AMAN (Acute motor axonal neuropathy)and AMSAN (acute motor-sensory axonal neuropathy)}, Kawasaki disease, and ITP (acute and chronic), among others.
By Regions : North America, Europe, APAC and Rest of the World.
Intravenous Immunoglobulin Market – Geographical Analysis
Globally, North America is the leading market for IVIg, accounting for the largest revenue pocket, followed by the Europe & Asia Pacific markets, respectively. The US market backed by the high expenditure on healthcare is the largest contributor to the regional market growth. Moreover, increasing prevalence of immunodeficiency disorder and rising demand for treatment measures provide impetus to the market growth.
On the other hand, Europe, the world’s second-largest market for IVIg, is fostered by the high per capita income and robust healthcare penetration in the region. The strong market growth in the countries like Germany & France drives the regional market growth, large scale. Attributing to the increasing investment in healthcare and rising number of patients with immune system diseases, the market is projected to register a phenomenal CAGR during the forecast period.
Asia Pacific market for the Intravenous Immunoglobulin is expected to perceive an exponential growth. Owing to the huge population and the burgeoning medical treatment market, India & China drive the regional market growth. Vietnam, Thailand, and Malaysia among the other South East Asian countries are projected to contribute significantly to the regional market growth. With the growing Medical Tourism markets in India & Malaysia the APAC region will register a significant CAGR during the review period.
Study objectives of Global Intravenous Immunoglobulin (IVIg) Market:
To provide detailed analysis of the Global Intravenous Immunoglobulin (IVIg) market structure along with forecast for the next 7 years of the various segments and sub-segments of the IVIG Market
To provide insights about the key drivers and restraints that affecting the growth of the IVIg market
To provide detail analysis of global IVIg market mainly based on Value chain analysis, PROTER’s five forces, Price analysis, and Supply Chain analysis etc.
To provide revenue of the market that includes historical as well as forecast revenue, on the basis of segments and sub segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide detail analysis of the market that segmented on the basis of type, application, and its sub-segments.
To provide detail country level analysis of the market with respect to the current market size and future prospective
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global IVIg Market
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137